Literature DB >> 22689969

Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations.

Bernd K Gilsbach1, Franz Y Ho, Ingrid R Vetter, Peter J M van Haastert, Alfred Wittinghofer, Arjan Kortholt.   

Abstract

Mutations in human leucine-rich-repeat kinase 2 (LRRK2) have been found to be the most frequent cause of late-onset Parkinson disease. Here we show that Dictyostelium discoideum Roco4 is a suitable model to study the structural and biochemical characteristics of the LRRK2 kinase and can be used for optimization of current and identification of new LRRK2 inhibitors. We have solved the structure of Roco4 kinase wild-type, Parkinson disease-related mutants G1179S and L1180T (G2019S and I2020T in LRRK2) and the structure of Roco4 kinase in complex with the LRRK2 inhibitor H1152. Taken together, our data give important insight in the LRRK2 activation mechanism and, most importantly, explain the G2019S-related increase in LRRK2 kinase activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689969      PMCID: PMC3387044          DOI: 10.1073/pnas.1203223109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

2.  Characterization of the Roco protein family in Dictyostelium discoideum.

Authors:  Wouter N van Egmond; Peter J M van Haastert
Journal:  Eukaryot Cell       Date:  2010-03-26

3.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

4.  Intramolecular activation mechanism of the Dictyostelium LRRK2 homolog Roco protein GbpC.

Authors:  Wouter N van Egmond; Arjan Kortholt; Katarzyna Plak; Leonard Bosgraaf; Sylvia Bosgraaf; Ineke Keizer-Gunnink; Peter J M van Haastert
Journal:  J Biol Chem       Date:  2008-08-14       Impact factor: 5.157

5.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase.

Authors:  Junpeng Deng; Patrick A Lewis; Elisa Greggio; Eli Sluch; Alexandra Beilina; Mark R Cookson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-29       Impact factor: 11.205

6.  Structure of the Roc-COR domain tandem of C. tepidum, a prokaryotic homologue of the human LRRK2 Parkinson kinase.

Authors:  Katja Gotthardt; Michael Weyand; Arjan Kortholt; Peter J M Van Haastert; Alfred Wittinghofer
Journal:  EMBO J       Date:  2008-07-24       Impact factor: 11.598

7.  The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation.

Authors:  Elisa Greggio; Ibardo Zambrano; Alice Kaganovich; Alexandra Beilina; Jean-Marc Taymans; Veronique Daniëls; Patrick Lewis; Shushant Jain; Jinhui Ding; Ali Syed; Kelly J Thomas; Veerle Baekelandt; Mark R Cookson
Journal:  J Biol Chem       Date:  2008-04-08       Impact factor: 5.157

8.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

9.  Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

Authors:  Xianming Deng; Nicolas Dzamko; Alan Prescott; Paul Davies; Qingsong Liu; Qingkai Yang; Jiing-Dwan Lee; Matthew P Patricelli; Tyzoon K Nomanbhoy; Dario R Alessi; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2011-03-06       Impact factor: 15.040

Review 10.  Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.

Authors:  Elisa Greggio; Mark R Cookson
Journal:  ASN Neuro       Date:  2009-04-14       Impact factor: 4.146

View more
  31 in total

1.  Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts.

Authors:  Giambattista Guaitoli; Francesco Raimondi; Bernd K Gilsbach; Yacob Gómez-Llorente; Egon Deyaert; Fabiana Renzi; Xianting Li; Adam Schaffner; Pravin Kumar Ankush Jagtap; Karsten Boldt; Felix von Zweydorf; Katja Gotthardt; Donald D Lorimer; Zhenyu Yue; Alex Burgin; Nebojsa Janjic; Michael Sattler; Wim Versées; Marius Ueffing; Iban Ubarretxena-Belandia; Arjan Kortholt; Christian Johannes Gloeckner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

2.  Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.

Authors:  Zhiyong Liu; Robert A Galemmo; Kyle B Fraser; Mark S Moehle; Saurabh Sen; Laura A Volpicelli-Daley; Lawrence J DeLucas; Larry J Ross; Jacob Valiyaveettil; Omar Moukha-Chafiq; Ashish K Pathak; Subramaniam Ananthan; Hollis Kezar; E Lucile White; Vandana Gupta; Joseph A Maddry; Mark J Suto; Andrew B West
Journal:  J Biol Chem       Date:  2014-09-16       Impact factor: 5.157

3.  LRRK2 autophosphorylation enhances its GTPase activity.

Authors:  Zhiyong Liu; James A Mobley; Lawrence J DeLucas; Richard A Kahn; Andrew B West
Journal:  FASEB J       Date:  2015-09-22       Impact factor: 5.191

4.  Structural and functional in silico analysis of LRRK2 missense substitutions.

Authors:  Fernando Cardona; Marta Tormos-Pérez; Jordi Pérez-Tur
Journal:  Mol Biol Rep       Date:  2014-02-02       Impact factor: 2.316

5.  The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.

Authors:  Zhiyong Liu; Andrew B West
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2016-12-08       Impact factor: 3.036

Review 6.  Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.

Authors:  An Phu Tran Nguyen; Darren J Moore
Journal:  Adv Neurobiol       Date:  2017

7.  Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.

Authors:  Min Liu; Samantha A Bender; Gregory D Cuny; Woody Sherman; Marcie Glicksman; Soumya S Ray
Journal:  Biochemistry       Date:  2013-03-01       Impact factor: 3.162

8.  The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.

Authors:  Kaela Kelly; Shijie Wang; Ravindra Boddu; Zhiyong Liu; Omar Moukha-Chafiq; Corinne Augelli-Szafran; Andrew B West
Journal:  Exp Neurol       Date:  2018-07-24       Impact factor: 5.330

9.  The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.

Authors:  Soumya Ray; Samantha Bender; Stephanie Kang; Regina Lin; Marcie A Glicksman; Min Liu
Journal:  J Biol Chem       Date:  2014-04-02       Impact factor: 5.157

10.  The In Situ Structure of Parkinson's Disease-Linked LRRK2.

Authors:  Reika Watanabe; Robert Buschauer; Jan Böhning; Martina Audagnotto; Keren Lasker; Tsan-Wen Lu; Daniela Boassa; Susan Taylor; Elizabeth Villa
Journal:  Cell       Date:  2020-08-11       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.